ninase [EC 3.7 .1.3 L-kynurenine hydrolase] increase the excretion of kynurenine, 3 -hydroxykynurenine, and xanthurenic acid into urine after tryptophan adminis tration (2) (3) (4) (5) . We have previously shown that in B6-deficient rat kynurenine and 3 -hydroxykynurenine were heavily accumulated after tryptophan injection and there was a possibility of producing xanthurenic acid in liver in view of the Km values of kynurenine aminotransferase, and the activities of kynureninase were further decreased (6) , probably by the xanthurenic acid accumulated (7) .
Kynurenine metabolites were reported to be an inhibitor of various enzymes and metabolisms (8) (9) (10) (11) (12) (13) . Murakami and Kotake (14) indicated that xanthurenic acid caused diabetes through the formation of xanthurenic acid-insulin complex. Xanthurenic acid in urine after tryptophan administration is thought to be an index of vitamin B6 deficiency (15) . However, there is no report with respect to the contents of kynurenine, 3-hydroxykynurenine, and xanthurenic acid in kidney after tryptophan administration; only the amounts of some metabolites in urine and plasma are reported.
Elucidating the kynurenine metabolism in B6-deficient rat kidney after tryp tophan administration and the relationship of kynurenine metabolism between liver and kidney, we determined the contents of kynurenine, 3-hydroxykynurenine, kynurenic acid, and xanthurenic acid, and the activities of kynureninase and kynurenine aminotransferase in this study. MATERIALS Contents of kynurenic acid and xanthurenic acid The contents of kynurenic acid and xanthurenic acid in normal liver, plasma, and kidney after tryptophan injection are shown in Table 1 . In these organs both kynurenic and xanthurenic acids increased and kynurenic acid contents were higher than xanthurenic acid contents after injection.
AND METHODS

Chemicals
The changes of the contents of kynurenic acid and xanthurenic acid in B6 -deficient liver and plasma are shown in Fig. 3A . In both B6-deficient organs, the contents of kynurenic acid reached the maximum value at 2 to 3h after injection, and their changes were parallel to each other. The content of kynurenic acid in B6 -deficient liver at 2h was about 4.6 times greater than that in normal liver, but its content in B6-deficient plasma was similar to that in normal plasma. The changes of xanthurenic acid contents in both B6-deficient organs were also parallel and its content showed the maximum value at 3h after injection. Xanthurenic acid contents in B6-deficient organs were much higher than those in normal organs. Figure 3B shows the changes of the contents of kynurenic acid and xanthurenic acid in B6-deficient kidney. Both contents were much higher than those in normal Significance of difference between the values for the tryptophan-injected group and those for the non-injected group is denoted by *p<001 (t-test) . Activities of kynureninase After tryptophan injection, total activities that were determined with the addition of pyridoxal phosphate decreased, and normal kynureninase holoenzyme activity increased statistically, but B6-deficient holoenzyme activity was unchanged ( Table 2 ). The kynureninase activity in rat kidney cytosol was very low compared with that in liver cytosol, and saturation level of normal kidney kynureninase with pyridoxal phosphate was half that in liver enzyme (6) . Moreover, the decrease of saturation level with pyridoxal phosphate observed in B6-deficient liver enzyme after tryptophan injection could not be detected in B6-deficient kidney enzyme .
Activities of kynurenine amino transferase
The changes in activities of kynurenine aminotransferase in kidney cytosol and mitochondria after tryptophan injection are shown in Table 3 . Both normal rat enzyme activities in normal cytosol and mitochondria increased statistically regard less of the addition of pyridoxal phosphate. However, in B6-deficient kidney, all activities showed no change. Normal kidney cytosol contained 5 times greater total Vol. 35, No. 2, 1989 a Pyridoxal phosphate . Significances of differences between the values for the tryptophan-injected group and those for the non-injected group are denoted by *p<0 .05, **p<0.01, and ***p<0.001 (t-test).
activity than its mitochondria, and B6-deficient cytosol contained 3.6 times greater total activity. However, holoenzyme activity of kynurenine aminotransferase in normal kidney cytosol was 73% of that in mitochondria, and that in B6-deficient kidney cytosol was only 30%. Thus, although the B6 deficiency greatly decreased both total and holoenzyme activities of kynurenine aminotransferase in kidney cytosol, it did not decrease the total activity of mitochondrial kynurenine amino transferase and decreased the holoenzyme activity of that in kidney mitochondria to only 55% of the normal level, Therefore, mitochondrial kynurenine amino transferase activity was 3.4 times higher than that of cytosolic enzyme in the B6 -deficient kidney.
DISCUSSION
The liver is an important organ regulating the tryptophan level in plasma and brain becasue the liver includes tryptophan 2, 3-dioxygenase [EC 1 .13.11.11, L -tryptophan e oxygen 2, 3-oxidoreductase (decyclizing)], which is controlled by var ious factors (22, 23). Tryptophan 2, 3-dioxygenase is known to be a key enzyme in the tryptophan metabolism of the normal rat liver. Green et al. (24) reported that rat liver perfused with tryptophan produced a large amount of kynurenine and released it into the perfusate. In the B6-deficient rat liver, holoenzyme activity of kynureninase was decreased and the kynureninase level itself was also decreased (6). Stanley et al. (25) reported that the control strength of kynureninase in B6-deficient liver cell was higher than that of tryptophan 2, 3-dioxygenase . As we showed previously, excess tryptophan injection to B6-deficient rat led to the accumulation of a large quantity of kynurenine and 3-hydroxykynurenine in liver (6) . These indicated that liver metabolized tryptophan extremely and released its metabolites , especially kynurenine and 3-hydroxykynurenine, to the blood.
On the other hand, in the B6-deficient kidney, the accumulation of kynurenine and 3-hydroxykynurenine was very large and delayed compared with the B6 -deficient liver. Since the kidney does not contain tryptophan 2 , 3-dioxygenase and only includes very low indoleamine 2, 3-dioxygenase (26) , kynurenine accumulated in the normal and the B6-deficient kidney after tryptophan injection must come from the blood. Each change in kynurenine and 3-hydroxykynurenine contents in B6-deficient plasma paralleled each one in the B6-deficient kidney , but not in the B6 -deficient liver. Moreover, kynurenine 3-monooxygenase, which catalyzed the hydroxylation of kynurenine to 3-hydroxykynurenine , was inhibited with xanthu renic acid and kynurenic acid (27). Therefore, kynurenine and 3-hydroxykynurenine accumulated in the B6-deficient kidney seemed to be mainly derived from blood in addition to small amounts of their de novo synthesis. Total kynureninase activity in both normal and B6-deficient kidney was decreased and the holoenzyme activity in B6-deficient kidney was unchanged by tryptophan injection, while normal liver kynureninase activities were increased and B6-deficient liver holoenzyme activity was decreased exactly (6) . The decrease in total kynureninase activity in B6-deficient kidney seemed to be caused by the strong substrate inhibition in the presence of a high concentration of 3-hydroxykynurenine in assay mixture (21). However, kynurenine aminotransferase could not be inhibited by both substrates even if their concentration was 8mM (20). The kynureninase holoenzyme activity in B6-deficient kidney was lower than in B6-deficient liver and showed no change after tryptophan injection. This holoenzyme activity was very low and nearly equal to a detectable limit of our assay method, so it seemed to be unable to detect the change in the activity. Therefore, these seemed to cause the apparent increase of saturation level with pyridoxal phosphate in B6-deficient kidney after tryptophan injection. Moreover, the effects of tryptophan adminis tration on the activities of normal kidney kynureninase and B6-deficient kidney mitochondrial kynurenine aminotransferase were different from those in the liver (6) . Although the reason for these differences is unknown, the responsiveness to tryptophan injection seemed to be different between liver and kidney.
B6 deficiency decreased both kynureninase and kynurenine aminotransferase activities in kidney except for the total activity of mitochondrial kynurenine aminotransferase. Holoenyzme activity of kynurenine aminotransferase in B6 -deficient kidney mitochondria was higher than that of cytosolic enzyme as reported peviously (2, 29) , and higher than that of B6-deficient liver mitochondria (17.2 -23.5nmol/min g of liver) (6) . With regard to production of xanthurenic acid and kynurenic acid, therefore, B6-deficient kidney has favorable conditions compared with B6-deficient liver. 3-Hydroxykynurenine concentration was estimated to be 5.7mM at 3h when the water content is assumed to be 70%, and the kynurenine concentration was only 1.1mM at 2h. 3-Hydroxykynurenine concentration in B6 -deficient liver was 2mM at 1-1.5h (6) . As Km values of purified kynurenine aminotransferase for kynurenine and 3-hydroxykynurenine were high-reported to be 4.3 and 5.7mM, respectively (20)-the production rate of xanthurenic acid and kynurenic acid was dependent upon each substrate concentration in the organ. In fact, xanthurenic acid and kynurenic acid could be detected in both B6-deficient liver and kidney, and their kidney contents were 6 to 34 times greater than in the liver.
In conclusion, liver metabolizes tryptophan to mainly kynurenine in normal rat, or to kynurenine, 3-hydroxykynurenine, and xanthurenic acid in B6-deficient rat, and then further metabolizes or releases them into the blood after tryptophan injection. The kidney collects the metabolites, and metabolizes to each further metabolite, especially xanthurenic acid, or excretes them into urine. B6-deficient kidney after tryptophan injection provided advantageous conditions for the acti vities of kynureninase and kynurenine aminotransferase and substrate concen tration in order to produce xanthurenic acid, compared with the B6-deficient liver.
